<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776243</url>
  </required_header>
  <id_info>
    <org_study_id>KCMC08MI168</org_study_id>
    <secondary_id>VCMC08OT066</secondary_id>
    <nct_id>NCT00776243</nct_id>
  </id_info>
  <brief_title>Short-term Effect of Intensive Insulin Therapy on Incretin Secretion</brief_title>
  <official_title>Short-term Effect of Intensive Insulin Therapy on Incretin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In type 2 diabetic patients, abnormality in secretion or action of incretin(GLP-1, GIP) is
      observed. Although controversy still exists, the secretion of GLP-1 is thought to be reduced
      by 20-30% while GIP secretion is normal or slightly elevated, in type 2 diabetic patients.
      Various parameters such as the duration of diabetes, the amount of meal and their
      constitution, gastric bypass surgery, and some antidiabetic drugs affect the secretion of
      incretin. However, the secretion of GLP-1 and GIP in glucotoxic condition and whether they
      recover after improvement of glycemic status is not known. The investigators aim to study the
      effect of intensive insulin treatment in uncontrolled diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of incretin secretion before and after intensive insulin therapy</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in incretin secretion according to the duration of diabetes</measure>
    <time_frame>basal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors affecting incretin secretion</measure>
    <time_frame>basal</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>wDM</arm_group_label>
    <description>Early diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pDM</arm_group_label>
    <description>Poorly controlled diabetic patients</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Subjects with normal glucose tolerance

          2. Early diabetic patients with disease duration of less than 5years

          3. Uncontrolled diabetic patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetic patients with disease duration of less than 15years

          -  age of 20-70 years

          -  BMI 22-27

          -  HbA1c 9-13%

          -  patients willing to receive intensive glucose control

          -  patients who are able to monitor their glucose level at home

               -  for normal glucose tolerance group : NGT subjects with same range of age and BMI

               -  for early diabetes group : patients with diabetic duration of less than 5 years
                  and HbA1c level less than 7.5% for at least last 6 months

        Exclusion Criteria:

          -  previous history of insulin treatment

          -  patients taking alpha-glucosidase inhibitor or thiazolidinedione

          -  serum creatinine &gt;= 1.5 mg/dL

          -  hemoglobin &lt; 10 g/dL

          -  AST/ALT greater than 3 times normal range

          -  ischemic heart disease, congestive heart failure (NYHA grade &gt;=2)

          -  chronic renal failure, proliferative diabetic retinopathy, CVA

          -  patients with gastroparesis or taking medications altering gastric motility

          -  usage of steroid or other agents affecting glucose metabolism

          -  pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun-Ho Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Endocrinology and Metabolism, St.Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Kyonggi-do</state>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Endocrinology and Metabolism, Kangnam St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Meier JJ, Nauck MA. Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):606-7. doi: 10.1038/ncpendmet0946. Epub 2008 Aug 26.</citation>
    <PMID>18725906</PMID>
  </reference>
  <reference>
    <citation>Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008 Mar;57(3):678-87. Epub 2007 Dec 5.</citation>
    <PMID>18057091</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004 Dec;53 Suppl 3:S190-6. Review.</citation>
    <PMID>15561910</PMID>
  </reference>
  <reference>
    <citation>Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23.</citation>
    <PMID>11502801</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>May 10, 2010</last_update_submitted>
  <last_update_submitted_qc>May 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kun-Ho Yoon</name_title>
    <organization>Kangnam St.Mary's hospital</organization>
  </responsible_party>
  <keyword>incretin</keyword>
  <keyword>GLP-1</keyword>
  <keyword>GIP</keyword>
  <keyword>intensive insulin therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

